Biofrontera Posts Strong Q2 2026 on 33% Revenue Growth
Event summary
- Q2 revenue rose 33% YoY to $12.0M, driven by Ameluz® demand and price increases.
- Gross margin improved 920 basis points to 80%, reflecting lower Ameluz® costs post-Strategic Transaction.
- Net loss narrowed to $0.6M from $5.3M YoY; Adjusted EBITDA neared breakeven at $(0.2)M.
- First-half revenue grew 25% YoY to $22.1M, with operating cash burn down 76% YoY.
The big picture
Biofrontera’s Q2 results reflect the strategic benefits of its October 2025 transaction with Biofrontera AG, which lowered Ameluz® costs and improved margins. The company is now positioned to capitalize on expanding PDT applications in dermatology, though regulatory hurdles and execution risks remain critical watchpoints.
What we're watching
- Regulatory Risk
- The ITC exclusion order on the RhodoLED XL lamp may disrupt supply, though Biofrontera is pursuing a remediation plan.
- Pipeline Progress
- Approval timing for Ameluz® in superficial basal cell carcinoma (sBCC) by PDUFA date in late September 2026 will shape Q1 2027 launch plans.
- Operational Efficiency
- The pace at which Biofrontera sustains cost discipline and commercial execution will determine its path to cash flow breakeven in 2026.